RecruitingPhase 3NCT07012629

A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)

A EUROpean Pragmatic Multicenter Randomized Trial on Platelet Inhibition and/or Lipid Lowering Treatment in Covert Brain Infarction (CBI)


Sponsor

Aarhus University Hospital

Enrollment

1,652 participants

Start Date

Nov 26, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Magnetic resonance imaging (MRI) is commonly used in healthcare, and sometimes it shows small areas of brain damage called Covert Brain Infarcts (CBIs). These are usually found by chance when people have scans for things like headaches or dizziness. Although CBIs don't cause symptoms at the time, they are linked to a higher risk of future stroke and death. There is currently no standard treatment for CBIs, and doctors have different approaches-some give stroke-preventing medication (like antiplatelets or statins), while others don't treat at all. This is mostly because there isn't enough research yet. This study will test whether stroke-preventing treatments help people with CBIs. It will also look at whether having a CBI increases the risk of dementia, and whether treatment might lower that risk.


Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atorvastatin, a drug called Clopidogrel, and others for people with covert brain infarction. The study is currently recruiting participants at 14 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGacetylsalicyclic acid (ASA)

Daily dose 75 mg to 100 mg p.o.

DRUGClopidogrel

Daily dose 75 mg p.o.

DRUGRosuvastatin

Daily dose 20 mg p.o. (10 mg once daily for the first 4 weeks, then 20 mg once daily for the remainder of the study period if tolerated). If Rosuvastatin 20 mg is not tolerated, a dose reduction to 10 mg is allowed.

DRUGAtorvastatin

Daily dose 40 mg p.o. If Atorvastatin 40 mg is not tolerated, a dose reduction to 20 mg is allowed.


Locations(14)

Aalborg Universitetshospital

Aalborg, Denmark

Aarhus Universitetshospital

Aarhus, Denmark

Aarhus University Hospital

Aarhus, Denmark

Rigshospitalet

Copenhagen, Denmark

Bispebjerg og Frederiksberg Hospital

Copenhagen, Denmark

Herlev Hospital

Herlev, Denmark

Regionshospitalet Gødstrup

Herning, Denmark

Kolding Hospital

Kolding, Denmark

Odense Universitetshospital

Odense, Denmark

Roskilde Hospital

Roskilde, Denmark

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

Oslo University Hospital

Oslo, Norway

Skånes Universitetssjukhus

Lund, Sweden

Universitätsspital - Inselspital - University of Bern

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07012629


Related Trials